Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus induction and consolidation chemotherapy in newly diagnosed FLT3 mutation-negative acute myeloid leukemia
2017-003540-21Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Midostaurin plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Event-free survival. Started Feb 2018; status: terminated.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-003540-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003540-21.